Sydney Lepkin
👤 SpeakerAppearances Over Time
Podcast Appearances
President Trump announced drug maker EMD Sirono has agreed to lower prices for its fertility drugs, like Gonal-F, sold directly to patients not using their insurance.
All told, the company's IVF drugs will be offered at an 84% discount.
But the deal doesn't include EMD Sirono's other drugs for things like cancer and multiple sclerosis.
The announcement is part of the president's push to bring U.S.
drug prices in line with those paid in other countries, an effort he calls most favored nation pricing.
and it follows his campaign promise to make IVF more affordable.
A typical IVF cycle can cost as much as $30,000, and while drugs are part of that, they aren't the majority of the total cost.
For its part, EMD Sirono will get an expedited FDA review of a new drug and relief from certain tariffs.
AstraZeneca will give lower prices to Medicaid and offer some of its prescription drugs directly to consumers at a discount.
The company says those prices would be up to 80% less than its list prices.
In return, AstraZeneca will get a three-year exemption from certain tariffs.
This is part of the Trump administration's wider initiative to bring American drug prices more in line with those paid in other developed countries.
The White House's first deal was with Pfizer and was announced last month.
The administration is also setting up a website called TrumpRx to help patients find drug makers selling drugs directly to patients at lower prices.
Eli Lilly is announcing that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants' A1c, a measure of blood sugar control, better than placebo. The trial lasted 40 weeks and was only for people with type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Manjaro.
Eli Lilly is announcing that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants' A1c, a measure of blood sugar control, better than placebo. The trial lasted 40 weeks and was only for people with type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Manjaro.
The once-daily pill also helped patients lose up to 16 pounds. The company plans to report the results at the American Diabetes Association conference and publish them in a peer-reviewed medical journal later this year. Sydney Lepkin, NPR News.